Choksi Laborator

What is the technical trend for Choksi Laborator?

As of June 3, 2025, Choksi Laborator's technical trend has shifted to bullish, supported by strong daily moving averages and monthly indicators, despite some mildly bearish signals on the weekly MACD and KST.

As of 3 June 2025, the technical trend for Choksi Laborator has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The daily moving averages are bullish, and both the weekly and monthly Bollinger Bands confirm a bullish trend. Despite the weekly MACD and KST showing mildly bearish signals, the monthly MACD and KST are bullish, reinforcing the overall positive outlook. Dow Theory also indicates a bullish trend on both weekly and monthly time frames. The stock has shown significant returns compared to the Sensex, further highlighting its strength in the market.

how big is Choksi Laborator?

As of March 2024, Choksi Laboratories Ltd has a market capitalization of 100.00 Cr, with net sales of 41.50 Cr and a net profit of 1.29 Cr over the last four quarters. Shareholder's funds are valued at 22.21 Cr, and total assets amount to 61.56 Cr.

Market Cap: Choksi Laboratories Ltd has a market capitalization of 100.00 Cr, which classifies it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 41.50 Cr, and the sum of Net Profit for the same period is 1.29 Cr. This data is based on Standalone financials.<BR><BR>Balance Sheet Snapshot: This is Standalone data for the reporting period of March 2024. Shareholder's Funds are valued at 22.21 Cr, and Total Assets amount to 61.56 Cr.

Who are in the management team of Choksi Laborator?

As of March 2023, the management team of Choksi Laborator includes Sunil Choksi (Managing Director & CEO), Stela Choksi, Vyangesh Choksi (CFO), Himika Choksi, and several independent directors, overseeing the company's operations and governance.

As of March 2023, the management team of Choksi Laborator consists of the following individuals:<BR><BR>1. Sunil Choksi - Managing Director & CEO<BR>2. Stela Choksi - Whole-time Director<BR>3. Vyangesh Choksi - Whole Time Director & CFO<BR>4. Sudarshan Shastri - Independent Director<BR>5. N K Mani - Independent Director<BR>6. Himika Choksi - Whole-time Director<BR>7. Raghmendra Singh - Independent Director<BR>8. Prakhar Dubey - Company Secretary & Compliance Officer<BR>9. Meenaxi Patidar - Independent Director<BR><BR>This team includes a mix of executive and independent directors, overseeing various aspects of the company's operations and governance.

What does Choksi Laborator do?

Choksi Laboratories Ltd provides contract testing and analytical services in the healthcare sector and has a market cap of Rs 105 Cr. As of December 2024, it reported net sales of 10 Cr and a net profit of 0 Cr.

Overview:<BR>Choksi Laboratories Ltd provides contract testing and analytical services in the healthcare services industry and is categorized as a micro-cap company.<BR><BR>History:<BR>Incorporated on 29 January 1993, Choksi Laboratories Ltd has been operational since its inception. The latest quarterly results reported net sales and net profit for December 2024.<BR><BR>Financial Snapshot:<BR>Net Sales: 10 Cr (Quarterly Results - Dec 2024) <BR>Net Profit: 0 Cr (Quarterly Results - Dec 2024) <BR>Market Cap: Rs 105 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 74.00 <BR>Industry P/E: 54 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 1.26 <BR>Return on Equity: 5.60% <BR>Price to Book: 4.14 <BR><BR>Contact Details:<BR>Address: Survey no 9/1 Gram Kumerdi, Near to Tulshiyana Indl Park Indore Madhya Pradesh : 452010 <BR>Email: compliance_officer@choksi.com <BR>Website: http://www.choksilab.com

Has Choksi Laborator declared dividend?

No Dividend History Available

Who are the peers of the Choksi Laborator?

Choksi Laborator's peers include Syngene Intl., Dr Lal Pathlabs, and Poly Medicure, among others. Choksi Laborator has the highest 1-year return at 115.17%, while most peers show below-average growth and varying management risks.

Peers: The peers of Choksi Laborator are Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Jeevan Scienti., Aspira Pathlab, N G Industries, Centenial Surgic.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Lal Pathlabs, while Good management risk is found at Syngene Intl., Poly Medicure, Indegene, and Vijaya Diagnost., and the rest have Below Average or Average management risk. Growth is Below Average for Syngene Intl., Dr Lal Pathlabs, Vijaya Diagnost., Jeevan Scienti., Aspira Pathlab, and the rest, while Average growth is noted for Poly Medicure, Indegene, Choksi Laborator, and N G Industries. Excellent capital structure is seen at Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., and the rest have Below Average or Average capital structure.<BR><BR>Return Snapshot: Choksi Laborator has the highest 1-year return at 115.17%, while Jeevan Scienti. has the lowest at -19.28%. Compared to its peers, Choksi Laborator's return is significantly higher. Additionally, the peers with negative six-month returns include Syngene Intl., Poly Medicure, Vijaya Diagnost., Jeevan Scienti., Aspira Pathlab, and Deccan Healthcar.

Who are the top shareholders of the Choksi Laborator?

The top shareholders of Choksi Laborator include promoter Sunil Choksi with 7.51% and public shareholder Sachin Seth with 3.96%. Individual investors hold 52.67%, while foreign institutional investors own 1.94%, and there are no mutual funds invested in the company.

The top shareholders of Choksi Laborator include Sunil Choksi, who is the promoter with the highest holding at 7.51%. Following him, Sachin Seth is the highest public shareholder with a stake of 3.96%. Additionally, individual investors collectively hold a significant portion of the company at 52.67%. The company also has 1.94% held by foreign institutional investors (FIIs), but there are no mutual funds currently invested in it.

Are Choksi Laborator latest results good or bad?

Choksi Laboratories' latest results are mixed; while Profit After Tax increased slightly, net sales growth slowed significantly and standalone net profit declined. Overall, the performance suggests challenges in the healthcare sector, leading to a 'Hold' recommendation on the stock.

Choksi Laboratories' latest financial results present a mixed picture. While the company has shown a slight increase in Profit After Tax (PAT) for the first half of the fiscal year, rising to Rs 1.31 crore from Rs 1.29 crore in the previous year, other key metrics indicate a decline in performance.<BR><BR>Net sales growth has slowed significantly to 4.66% compared to 21.63% in the same quarter last year, and standalone net profit has decreased by 7.14%. Additionally, the operating profit margin has also seen a slight decline. Overall, the company's score has dropped from 4 to 3, leading to a 'Hold' recommendation on the stock.<BR><BR>In summary, while there are some positive aspects, such as the increase in PAT, the overall flat performance and declining growth rates suggest that the results may not be considered strong. The company is navigating challenges in the healthcare services sector, which reflects in its financial performance.

Is Choksi Laborator overvalued or undervalued?

As of October 13, 2025, Choksi Laborator is rated attractive but considered overvalued with high valuation ratios, including a PE of 85.25, despite strong stock performance, especially when compared to peers like Apollo Hospitals and Max Healthcare.

As of 13 October 2025, the valuation grade for Choksi Laborator has moved from very attractive to attractive. The company is currently considered overvalued based on its high valuation ratios. The PE ratio stands at 85.25, while the Price to Book Value is 5.42, and the EV to EBIT is 33.62, all indicating a premium valuation compared to its peers.<BR><BR>In comparison, Apollo Hospitals, which is also rated attractive, has a significantly lower PE ratio of 70.2 and an EV to EBITDA of 36.12. Max Healthcare, rated as very expensive, has a PE ratio of 92.33, but its high valuation does not justify the premium over Choksi Laborator. Despite Choksi's impressive stock performance, with a year-to-date return of 144.57% compared to the Sensex's 5.36%, the elevated valuation ratios suggest that the stock may be overvalued in the current market environment.

When is the next results date for Choksi Laborator?

Choksi Laborator will announce its results on 14 November 2025.

Choksi Laborator is scheduled to declare its results on 14 November 2025.

How has been the historical performance of Choksi Laborator?

Choksi Laborator has experienced growth in net sales and operating income from Mar'21 to Mar'25, but its profitability metrics, including profit before and after tax, have fluctuated significantly. The company needs to focus on cost management and operational efficiency despite improved cash flow from operating activities.

Answer:<BR>The historical performance of Choksi Laborator shows a mixed trend over the years, with notable fluctuations in revenue and profitability.<BR><BR>Breakdown:<BR>Choksi Laborator's net sales have shown a consistent upward trajectory, increasing from 25.69 Cr in Mar'21 to 41.78 Cr in Mar'25. Total operating income followed a similar pattern, rising from 28.49 Cr in Mar'20 to 41.78 Cr in Mar'25. The company's operating profit (PBDIT) has also improved, reaching 11.30 Cr in Mar'25 from 3.17 Cr in Mar'20, although the operating profit margin has slightly decreased from 29.73% in Mar'23 to 26.88% in Mar'25. Profit before tax fluctuated significantly, peaking at 3.72 Cr in Mar'23 before dropping to 2.15 Cr in Mar'25. Profit after tax also saw a decline from 3.21 Cr in Mar'23 to 1.52 Cr in Mar'25. The company's total liabilities increased from 59.49 Cr in Mar'23 to 64.79 Cr in Mar'25, while total assets rose from 59.49 Cr to 64.79 Cr in the same period. Cash flow from operating activities improved to 11.00 Cr in Mar'25, maintaining stability compared to previous years. Overall, while Choksi Laborator has shown growth in sales and operating income, its profitability metrics have experienced volatility, indicating a need for strategic focus on cost management and operational efficiency.

Should I buy, sell or hold Choksi Laborator?

Which are the latest news on Choksi Laborator?

Why is Choksi Laboratories Ltd falling/rising?

As of 01-Feb, Choksi Laboratories Ltd's stock price is currently Rs 121.00, reflecting a 1.38% increase and a strong performance with a 9.01% rise over the past week. Despite recent gains, concerns about long-term fundamentals persist, including low returns on capital and high debt levels.

As of 01-Feb, Choksi Laboratories Ltd's stock price is rising, currently at Rs 121.00, reflecting a change of 1.65 (1.38%) upward. The stock has shown a strong performance over the past week, with a notable increase of 9.01%, while the benchmark Sensex has declined by 1.00%. Additionally, the stock has been gaining for the last three days, accumulating a total return of 6.84% during this period.<BR><BR>Today's trading activity indicates that the stock outperformed its sector by 1.72%. It reached an intraday high of Rs 122.45, which is a 2.6% increase, although it also experienced a low of Rs 111.55, reflecting a decline of 6.54%. Despite this volatility, the overall trend appears positive, supported by recent positive financial results, including the highest operating cash flow and return on capital employed reported in September.<BR><BR>However, it is important to note that while the stock is currently rising, there are underlying concerns regarding its long-term fundamentals, such as a relatively low average return on capital employed and a high debt to EBITDA ratio. Despite these factors, the stock is trading at a discount compared to its peers, which may contribute to its current upward movement.